242 related articles for article (PubMed ID: 22647638)
1. Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination.
Fraison JB; Guilpain P; Schiffmann A; Veyrac M; Le Moing V; Rispail P; Le Quellec A
J Crohns Colitis; 2013 Feb; 7(1):e11-4. PubMed ID: 22647638
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab.
Desales AL; Mendez-Navarro J; Méndez-Tovar LJ; Ortiz-Olvera NX; Cullen G; Ocampo J; Lemus W; Tun AE; Mayoral-Zavala A; Dehesa-Violante M
J Crohns Colitis; 2012 May; 6(4):483-7. PubMed ID: 22398055
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
4. Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab.
Vázquez-Morón JM; Pallarés-Manrique H; Martín-Suárez IJ; Benítez-Rodríguez B; Ramos-Lora M
Rev Esp Enferm Dig; 2013; 105(5):299-302. PubMed ID: 23971663
[TBL] [Abstract][Full Text] [Related]
5. Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine.
Abou Zahr A; Saad Aldin E; Yunyongying P
Int J Infect Dis; 2013 Aug; 17(8):e650-2. PubMed ID: 23769453
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
[TBL] [Abstract][Full Text] [Related]
8. Cavitary pulmonary cryptococcosis with an Aspergillus fungus ball.
Makino Y; Nishiyama O; Sano H; Iwanaga T; Higashimoto Y; Kume H; Tohda Y
Intern Med; 2014; 53(23):2737-9. PubMed ID: 25447660
[TBL] [Abstract][Full Text] [Related]
9. Disseminated cryptococcosis in Crohn's disease: a case report.
Chavapradit N; Angkasekwinai N
BMC Infect Dis; 2018 Dec; 18(1):620. PubMed ID: 30514241
[TBL] [Abstract][Full Text] [Related]
10. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
11. [Severe lymphopenia in a patient with Crohn's disease].
Monasterio C; Kreisel W; Hasselblatt P
Internist (Berl); 2018 Aug; 59(8):857-860. PubMed ID: 29356833
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.
Verma S; Kroeker KI; Fedorak RN
BMC Gastroenterol; 2013 Apr; 13():59. PubMed ID: 23556424
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
[TBL] [Abstract][Full Text] [Related]
14. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?
Fiorino G; Danese S
J Crohns Colitis; 2016 Nov; 10(11):1257-1258. PubMed ID: 27389085
[No Abstract] [Full Text] [Related]
16. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
[TBL] [Abstract][Full Text] [Related]
17. Vulval Crohn's disease: a clinical study of 22 patients.
Laftah Z; Bailey C; Zaheri S; Setterfield J; Fuller LC; Lewis F
J Crohns Colitis; 2015 Apr; 9(4):318-25. PubMed ID: 25687208
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
19. Disseminated Cryptococcus neoformans infection and Crohn's disease in an immunocompetent patient.
Sciaudone G; Pellino G; Guadagni I; Somma A; D'Armiento FP; Selvaggi F
J Crohns Colitis; 2011 Feb; 5(1):60-3. PubMed ID: 21272807
[TBL] [Abstract][Full Text] [Related]
20. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
